title: ProFESS trial: any lessons to learn for future anti-platelet trials?
authors.affiliation: Department of Medicine, Newark Hospital, Boundary Hospital, Newark, Notts, UK. jagdish.sharma@sfh-tr.nhs.uk
authors.forename: J C
authors.initials: JC
authors.lastname: Sharma
authors.forename: M
authors.initials: M
authors.lastname: Vassallo
authors.forename: I N
authors.initials: IN
authors.lastname: Ross
mesh_terms: D000368:Aged; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D002536:Cerebral Arteries / Q000473:pathology; D000077144:Clopidogrel; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors; D040242:Risk Reduction Behavior; D020521:Stroke / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin